Fig. 4From: Trastuzumab and fulvestrant combination therapy for women with advanced breast cancer positive for hormone receptor and human epidermal growth factor receptor 2: a retrospective single-center studyPFS subgroup analysis by number of treatment line. Kaplan–Meier curves of PFS in patients who received fulvestrant and trastuzumab combination therapy as ≤3 line treatment or > 3 line treatmentBack to article page